drugset / Trial / NCT03805984
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
Phase 1
Completed
60 enrolled
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations · collab
RandomizedSequentialTriple-blindPrevention
Summary
This is a randomized and double-blinded within study group, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation using the CELLECTRA® 2000 device in healthy adult volunteers.
Timeline
- Start
- 2019-05-09
- Primary completion
- 2020-10-21
- Completion
- 2020-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO-4500 | Vaccine | 1 mg | Other |